Colorectal Cancer

Overview
Epidemiology
Pathophysiology
Etiology and Risk Factors
Clinical Presentation
Diagnosis
Treatment
Complications
Prognosis
Prevention
Recent Research and Advances
Research Papers
Connections
Featured Videos

1. Overview

Colorectal cancer (often shortened to CRC) is cancer that begins in the colon (the long part of the large intestine) or the rectum (the last several inches that connect the colon to the anus). Doctors group the two together because they share the same lining, the same major risk factors, and most of the same biology. When someone says "colon cancer" or "bowel cancer," they usually mean the same thing.

Here is the single most important fact about this disease, and the reason it gets so much attention from doctors: colorectal cancer is largely preventable, and when it is caught early it is largely curable. It is one of the very few common cancers where a screening test can find and remove the problem before it ever becomes cancer. That is not true of most cancers. It is true here because of how slowly CRC usually develops.

In the United States, colorectal cancer is the second-leading cause of cancer death overall (counting men and women together) and the third most commonly diagnosed cancer. Roughly 1 in 24 Americans will develop it in their lifetime. The good news embedded in those grim numbers: deaths have fallen substantially since the 1980s, almost entirely because of screening. The troubling counter-trend, covered below, is a steady and unexplained rise in cases among younger adults — people in their 30s and 40s — which is why the recommended starting age for screening was lowered from 50 to 45.

This page explains, in plain language, how colorectal cancer forms, who is at risk, the warning signs you should never ignore, how the screening options honestly compare, and what modern treatment looks like — including a 2022 rectal-cancer trial that produced one of the most striking results in cancer medicine in years.

2. Epidemiology

Worldwide, colorectal cancer is the third most common cancer and the second-leading cause of cancer death, with roughly 1.9 million new cases and about 900,000 deaths each year as of 2020. Modeling published in Gut projects that the global burden will rise to about 3.2 million new cases and 1.6 million deaths annually by 2040, driven largely by population growth, aging, and the spread of "Western" diets and lifestyles to fast-developing countries.

In the United States, about 150,000 people are diagnosed each year and roughly 53,000 die of the disease. The lifetime risk is approximately 4% for men and women combined. Incidence is slightly higher in men than women and higher in Black Americans than in other groups — a disparity driven by differences in screening access, follow-up of abnormal results, and other factors rather than by biology alone.

The early-onset trend. Since the mid-1990s, CRC rates have been falling in adults over 65 (the screening success story) but rising in adults under 50 — a pattern documented across the United States, Europe, Australia, and other high-income countries. Someone born around 1990 has roughly double the risk of colon cancer and quadruple the risk of rectal cancer compared with someone born around 1950 at the same age. Researchers do not yet have a single clear explanation; suspects include obesity, diet, antibiotic and gut-microbiome changes, and exposures in childhood. Whatever the cause, the practical response was concrete: in 2021 the U.S. Preventive Services Task Force lowered the recommended age to begin screening from 50 to 45 for people at average risk.

3. Pathophysiology

Almost all colorectal cancers (more than 95%) are adenocarcinomas — cancers that arise from the gland cells lining the bowel. What makes CRC special, and screenable, is that it usually does not appear out of nowhere. It develops through a slow, stepwise process called the adenoma-to-carcinoma sequence.

It works like this. The normal lining of the colon renews itself constantly. Occasionally a cell picks up a genetic mistake and starts growing into a small, benign lump called a polyp. The most important type is the adenomatous polyp (adenoma). Most polyps never turn into anything dangerous. But over years, a small fraction accumulate additional mutations — first in a gene called APC, then in KRAS, then in tumor-suppressor genes like TP53 — and step by step a harmless polyp transforms into an invasive cancer. This genetic roadmap was first described by Eric Fearon and Bert Vogelstein in 1990 and remains one of the foundational models in all of cancer biology.

The crucial number for patients is the timeline: this transformation typically takes 10 to 15 years. That long, slow window is exactly why screening works so well. A colonoscopy that finds and snips out an adenoma has interrupted a cancer a decade before it would have become dangerous. A test done every 10 years can stay ahead of a process that takes 10 to 15 years to complete. Very few cancers give doctors that kind of head start.

A second, faster pathway exists. Some cancers — particularly on the right side of the colon — develop through serrated polyps and a process of "microsatellite instability" (MSI), where the cell's DNA-repair machinery breaks down and mutations pile up rapidly. About 15% of CRCs are MSI-high / mismatch-repair-deficient (dMMR). This matters enormously for treatment, because these tumors respond dramatically to immunotherapy — a point we return to below.

4. Etiology and Risk Factors

Most colorectal cancer is sporadic — it happens by chance accumulation of mutations, shaped by age and lifestyle — rather than inherited. Only about 5% is caused by a clearly inherited syndrome. Here are the major risk factors, sorted by how much you can do about them.

Things you cannot change:

Age. Risk climbs steadily after 45–50, though, as noted, younger cases are rising.
Family history. Having a first-degree relative (parent, sibling, child) with CRC roughly doubles your risk and means you should start screening earlier.
Inflammatory bowel disease. Long-standing ulcerative colitis and Crohn's disease involving the colon raise risk substantially because chronic inflammation drives the lining to mutate. People with extensive IBD need earlier and more frequent surveillance colonoscopy.
Inherited syndromes. Lynch syndrome (hereditary nonpolyposis colorectal cancer) is the most common, caused by mismatch-repair gene mutations; it accounts for about 3% of cases and confers up to a 50–80% lifetime risk. Familial adenomatous polyposis (FAP), caused by an APC mutation, produces hundreds to thousands of polyps and a near-100% lifetime risk if the colon is not removed. People with these syndromes need genetic counseling and intensive surveillance.

Things you can influence:

Processed and red meat. In 2015 the World Health Organization's International Agency for Research on Cancer (IARC) classified processed meat (bacon, ham, hot dogs, deli meats) as a Group 1 carcinogen — the same category as tobacco for strength of evidence, though not the same magnitude of risk. Red meat was classified as Group 2A ("probably carcinogenic"). To keep this in perspective: roughly 50 grams of processed meat per day (about one hot dog) is associated with an 18% relative increase in CRC risk — meaningful at the population level, modest for any one person.
Low fiber, high refined carbohydrate. Diets rich in whole grains, legumes, fruits, and vegetables are consistently linked with lower risk. Fiber speeds transit, dilutes carcinogens, and feeds gut bacteria that produce protective short-chain fatty acids like butyrate.
Obesity. Excess body fat, especially abdominal fat, raises risk through chronic inflammation and insulin/insulin-like growth factor signaling. See obesity.
Physical inactivity. Regular exercise independently lowers colon-cancer risk by roughly 20–25%.
Alcohol and smoking. Both increase risk in a dose-dependent way; heavy alcohol use is a clear contributor, and smoking is linked particularly to rectal cancer and to polyp formation.
Type 2 diabetes. Independently associated with higher risk, likely via insulin resistance.

5. Clinical Presentation

Here is the hard truth that makes screening so important: early colorectal cancer usually causes no symptoms at all. By the time symptoms appear, the cancer is often more advanced. That is why you should not wait for symptoms to get screened — and why, if symptoms do appear, they deserve prompt attention rather than a wait-and-see approach.

Red-flag symptoms — do not ignore these:

Rectal bleeding or blood in the stool. Bright red blood, dark/tarry stools, or blood mixed into the stool. Yes, hemorrhoids are far more common — but bleeding should never simply be assumed to be hemorrhoids, especially after 45 or if it is new.
Iron-deficiency anemia, especially in a man or a postmenopausal woman. A slow bleed from a right-sided colon tumor often causes no visible blood but shows up as unexplained anemia and fatigue. In an older man or postmenopausal woman, iron-deficiency anemia is considered a colon cancer until proven otherwise.
A persistent change in bowel habits. New constipation or diarrhea, narrowing of the stool ("pencil-thin" stools), or a feeling that the bowel does not fully empty, lasting more than a few weeks.
Unexplained weight loss, persistent abdominal cramping, or a feeling of fullness.

Symptoms can differ by location. Right-sided (proximal) tumors tend to bleed slowly and present with anemia and fatigue; the colon is wide there, so obstruction is late. Left-sided and rectal tumors more often cause visible bleeding, changes in stool caliber, and obstruction, because the passage is narrower. A small but important number of cancers first announce themselves as a bowel obstruction or, rarely, a perforation — surgical emergencies.

6. Diagnosis

Diagnosis falls into two situations: screening (testing a healthy person with no symptoms) and diagnostic work-up (investigating someone who has symptoms or an abnormal screening test). The gold standard for both confirmation and tissue diagnosis is colonoscopy with biopsy.

Screening options, compared honestly

There is no single "best" screening test — the best test is genuinely the one you will actually do. Here is an honest comparison of the main options for average-risk people:

Colonoscopy — a flexible camera examines the entire colon, every 10 years for average-risk people. It is the only test that is both diagnostic and therapeutic: polyps found are removed on the spot, preventing cancer. It is the most sensitive option. Downsides: it requires a full bowel-cleansing prep (the part most people dread), sedation, a day off work, and carries a small risk of bleeding or perforation (roughly 1 in 1,000–3,000). It is also the most expensive up front. In the U.S. a screening colonoscopy is covered without copay under most insurance.
FIT (fecal immunochemical test) — a stool test done at home every year that detects hidden human blood. It is inexpensive (often free), needs no prep and no sedation, and is highly effective when repeated annually. Downside: a positive FIT requires a follow-up colonoscopy, and it is less sensitive than colonoscopy for polyps and early cancers in any single year.
Multitarget stool DNA test (Cologuard) — a mail-in stool test, every 3 years, that detects both blood and cancer-associated DNA changes. In the pivotal trial it found 92% of cancers (more than FIT's 74%), but at the cost of more false positives — it flagged abnormal results in many people who turned out to have nothing, each of whom then needs a colonoscopy. It is also considerably more expensive than FIT. Any positive result requires a follow-up colonoscopy.
CT colonography ("virtual colonoscopy") and flexible sigmoidoscopy are additional validated options used less commonly in current U.S. practice.

The NordICC nuance. In 2022 a large European randomized trial (NordICC) reported that inviting people to a single screening colonoscopy reduced their risk of being diagnosed with CRC by about 18% over 10 years — a smaller benefit than many expected, and the reduction in deaths did not reach statistical significance in that first analysis. This made headlines as colonoscopy being "less effective than thought." But there is an important catch: only 42% of those invited actually had the colonoscopy. When the analysts looked at people who actually underwent the procedure, the estimated reduction in CRC risk was about 31% and the reduction in CRC death about 50% — consistent with earlier evidence. The honest takeaway is not "skip colonoscopy" but "a screening test only helps if it is actually done." This is also why a simple yearly stool test that people reliably complete can rival a colonoscopy that people avoid.

Confirming and staging a cancer

Once a tumor is found, biopsy confirms the diagnosis under the microscope. Staging then determines how far it has spread, using the TNM system (Tumor depth, lymph Nodes, Metastasis), grouped into stages I–IV:

Stage I — cancer is confined to the inner layers of the bowel wall.
Stage II — it has grown through the wall but not to lymph nodes.
Stage III — it has reached nearby lymph nodes.
Stage IV — it has spread (metastasized) to distant organs, most often the liver and lungs. See metastatic cancers.

Staging uses CT scans of the chest, abdomen, and pelvis; rectal cancers add a pelvic MRI to judge how deeply the tumor invades. A blood test for CEA (carcinoembryonic antigen) is measured at baseline and tracked over time to monitor for recurrence. Every tumor should be tested for MMR/MSI status and key mutations (RAS, BRAF) because these directly shape treatment.

7. Treatment

Treatment depends heavily on stage and on whether the cancer is in the colon or the rectum (the rectum's tight location in the pelvis changes the approach). It is delivered by a team — surgeons, medical oncologists, radiation oncologists, and others.

Surgery

Surgery is the backbone of cure for stages I–III. The surgeon removes the segment of bowel containing the tumor along with its draining lymph nodes (a colectomy), then reconnects the healthy ends. Many operations are now done minimally invasively (laparoscopic or robotic). For early cancers caught at colonoscopy, the polyp removal itself can occasionally be curative. A permanent colostomy (a bag) is needed far less often than people fear — mostly for some low rectal cancers.

Chemotherapy for colon cancer

For stage III colon cancer (and selected high-risk stage II), chemotherapy after surgery reduces the chance of recurrence. The landmark MOSAIC trial (2004) established FOLFOX — the combination of folinic acid, fluorouracil (5-FU), and oxaliplatin — as the standard adjuvant regimen, improving survival over 5-FU alone. A common, fixable side effect of oxaliplatin is cold-triggered nerve tingling. The later IDEA collaboration (2018) showed that for many lower-risk stage III patients, 3 months of chemotherapy is nearly as good as 6 months, with far less nerve damage — a welcome example of treatment being safely de-escalated.

Treatment for advanced (stage IV) disease — matched to the tumor's biology

For metastatic CRC, treatment is now personalized by molecular testing:

Anti-EGFR antibodies by RAS status. Drugs like cetuximab and panitumumab block the EGFR growth signal — but only in tumors with a normal (wild-type) RAS gene. The pivotal work by Karapetis and colleagues (2008) showed that patients whose tumors carry a KRAS mutation get no benefit from cetuximab; giving it to them only adds toxicity. This is why every metastatic tumor is tested for RAS before these drugs are used — a textbook case of giving the right drug to the right patient.
Anti-angiogenic drugs such as bevacizumab, which starve the tumor of new blood vessels, are combined with chemotherapy regardless of RAS status.
Immunotherapy for MSI-high tumors. The roughly 15% of CRCs that are MSI-high/dMMR respond extraordinarily to immune-checkpoint drugs. In the KEYNOTE-177 trial (2020), first-line pembrolizumab doubled the time without disease progression compared with chemotherapy (about 16 months vs 8 months) in patients with MSI-high metastatic CRC — with fewer side effects. For this subgroup, immunotherapy is now the preferred first treatment.

Rectal cancer specifics

Rectal cancer is treated more intensively because the pelvis is tight and local recurrence is harder to manage. The modern approach for locally advanced rectal cancer is total neoadjuvant therapy (TNT) — giving all the chemotherapy and radiation before surgery. This shrinks tumors, improves the odds of clear surgical margins, and, remarkably, lets some patients avoid surgery altogether. In the OPRA trial (2022), roughly half of patients treated with TNT achieved a complete response and could be managed with close "watch-and-wait" surveillance instead of removing the rectum — preserving bowel and sexual function.

The most striking result came from a small 2022 trial led by Andrea Cercek and colleagues at Memorial Sloan Kettering. They gave the immunotherapy drug dostarlimab to patients whose rectal cancers were mismatch-repair-deficient (dMMR). Every single one of the first patients — 100% — had a complete clinical response, with no detectable tumor, and none needed chemotherapy, radiation, or surgery. The numbers were small and follow-up is ongoing, so this is not yet standard for everyone. But for this specific molecular subgroup it is one of the most remarkable results in the history of solid-tumor treatment.

8. Complications

Complications come from the cancer itself, from its spread, and from treatment:

Bowel obstruction or perforation — a tumor can block the bowel or, less often, perforate it, both surgical emergencies.
Chronic bleeding and iron-deficiency anemia — often the first clue to a right-sided cancer.
Metastasis — spread to the liver and lungs is the main cause of CRC death. See metastatic cancers.
Surgical and treatment effects — temporary or (rarely) permanent ostomy, changes in bowel function, oxaliplatin-related nerve damage, and, for pelvic radiation, effects on bladder and sexual function.
Recurrence — most relapses occur within the first 2–3 years, which is why surveillance with CEA, scans, and colonoscopy is intensive early on.

9. Prognosis

The single biggest driver of outcome is the stage at diagnosis — and that, in turn, is largely driven by whether the cancer was caught by screening or by symptoms. Here are honest 5-year relative survival figures (U.S. data), which mean the percentage of people alive 5 years after diagnosis compared with the general population:

Localized disease (no spread beyond the bowel): roughly 91% 5-year survival.
Regional disease (spread to nearby lymph nodes): roughly 73%.
Distant/metastatic disease (spread to liver, lung, etc.): roughly 16%.

The gap between 91% and 16% is the whole argument for screening, compressed into two numbers. A cancer caught early is usually curable; the same cancer caught after it has spread usually is not. Even for stage IV, however, outcomes have improved meaningfully over the past two decades thanks to better chemotherapy, targeted drugs, immunotherapy for the right subgroups, and aggressive surgery to remove isolated liver or lung metastases — some of which can still be curative.

10. Prevention

Few common cancers are as preventable as this one. Prevention works on two levels: screening (covered above — it removes precancerous polyps, which no diet or pill can match) and lifestyle. The honest evidence on lifestyle:

Fiber and whole foods — good evidence. Diets high in legumes, whole grains like oats, vegetables such as broccoli, and fruit are consistently linked with lower risk. The protective mechanisms (faster transit, butyrate production, dilution of carcinogens) are biologically plausible and supported by large cohorts.
Limit processed and red meat — good evidence. Following the IARC findings, cutting back on bacon, deli meats, and hot dogs is a sensible, evidence-based step.
Exercise and healthy weight — good evidence. Regular physical activity independently lowers colon-cancer risk by roughly 20%, and avoiding obesity removes a clear risk factor.
Aspirin — real but nuanced. Long-term low-dose aspirin reduces CRC incidence and death, and benefit appears strongest in tumors with PIK3CA mutations. But aspirin carries a genuine risk of gastrointestinal and brain bleeding, so it is not recommended for everyone — the decision should be individualized with a doctor who weighs your cardiovascular and bleeding risks. Do not start aspirin for cancer prevention on your own.
Vitamin D — promising but not proven. Higher vitamin D levels are associated with lower CRC risk in observational studies. But the strongest test of cause-and-effect — a randomized trial of calcium plus vitamin D by Baron and colleagues — did not reduce the recurrence of precancerous adenomas. So while maintaining adequate vitamin D is reasonable for general health, the honest statement is that supplements have not been proven to prevent colorectal cancer. The same trial did not show a clear protective effect for calcium on adenoma recurrence either.

Bottom line: eat more plants and fiber, move your body, keep a healthy weight, go easy on processed meat and alcohol, don't smoke — and, above all, get screened starting at 45 (or earlier if you have a family history or IBD). Screening is the one intervention proven to both prevent the disease and reduce death from it.

11. Recent Research and Advances

Colorectal cancer is one of the most active areas in oncology research, and several lines of work are changing practice:

The dostarlimab rectal-cancer result. The 2022 finding that immunotherapy alone produced a 100% complete response in mismatch-repair-deficient rectal cancer — sparing surgery, radiation, and chemo — is being expanded to other dMMR tumors and to colon cancer. If it holds up in larger trials, it could redefine treatment for this subgroup.
Liquid biopsy and circulating tumor DNA (ctDNA). Blood tests that detect tiny fragments of tumor DNA after surgery can reveal "minimal residual disease" — cancer cells too few to see on scans. Trials are testing whether ctDNA can tell doctors precisely who needs chemotherapy and who can safely skip it, sparing many patients unnecessary toxicity.
Treatment de-escalation. The IDEA result (3 vs 6 months of chemo) and watch-and-wait approaches for rectal cancer reflect a broader, patient-friendly shift: giving the least treatment that still cures, to preserve quality of life.
Understanding the early-onset surge. Intense research is probing why CRC is rising in younger adults — examining the gut microbiome, diet, antibiotics, processed foods, and early-life exposures — in hopes of both explaining and reversing the trend.
Blood-based screening. New blood tests for CRC screening are being developed and evaluated. They are more convenient than stool tests or colonoscopy but, so far, less sensitive for early cancers and precancerous polyps; their proper role is still being defined.

12. References & Research

Historical Background

The systematic study of colorectal cancer began at St Mark's Hospital in London in the early twentieth century. Surgeon John Percy Lockhart-Mummery and pathologist Cuthbert Dukes developed, in the 1930s, the first widely used staging system — Dukes' classification (A, B, C) — which linked how deeply a tumor invaded the bowel wall to a patient's likely survival, and which evolved into today's TNM staging. The modern molecular era opened in 1990, when Eric Fearon and Bert Vogelstein published their landmark genetic model showing that colorectal cancer develops through an orderly accumulation of mutations — the adenoma-to-carcinoma sequence — one of the most influential papers in cancer biology. The screening era that followed, validated by long-term studies showing that removing polyps prevents cancer deaths, turned colorectal cancer into one of the few cancers that can be stopped before it ever begins.

Key Research Papers

Siegel RL, Wagle NS, Cercek A, et al. Colorectal cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023;73(3):233-254.
Morgan E, Arnold M, Gini A, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023;72(2):338-344.
Siegel RL, Torre LA, Soerjomataram I, et al. Global patterns and trends in colorectal cancer incidence in young adults. Gut. 2019;68(12):2179-2185.
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-767.
Bouvard V, Loomis D, Guyton KZ, et al. Carcinogenicity of consumption of red and processed meat. The Lancet Oncology. 2015;16(16):1599-1600.
US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965-1977.
Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths. New England Journal of Medicine. 2012;366(8):687-696.
Bretthauer M, Løberg M, Wieszczy P, et al. Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death. New England Journal of Medicine. 2022;387(17):1547-1556.
Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget Stool DNA Testing for Colorectal-Cancer Screening. New England Journal of Medicine. 2014;370(14):1287-1297.
André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer (MOSAIC). New England Journal of Medicine. 2004;350(23):2343-2351.
Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. New England Journal of Medicine. 2008;359(17):1757-1765.
André T, Shiu K, Kim TW, et al. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer (KEYNOTE-177). New England Journal of Medicine. 2020;383(23):2207-2218.
Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy (OPRA). Journal of Clinical Oncology. 2022;40(23):2546-2556.
Cercek A, Lumish M, Sinopoli J, et al. PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. New England Journal of Medicine. 2022;386(25):2363-2376.
Liao X, Lochhead P, Nishihara R, et al. Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival. New England Journal of Medicine. 2012;367(17):1596-1606.
Baron JA, Barry EL, Mott LA, et al. A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. New England Journal of Medicine. 2015;373(16):1519-1530.

Research Papers

Colorectal cancer research evolves quickly. The links below run live searches on PubMed, the U.S. National Library of Medicine's database, so you can read the latest peer-reviewed studies on each topic. Each opens in a new tab.

Connections

Back to Table of Contents